SCHEMBL3486823

SCHEMBL3486823

CC(C)(C)OC(=O)C(NC(=O)c1ccc(N)cc1)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CA2 P00918 4/20 0.41
ADRB2 P07550 2/20 0.40
ADRB1 P08588 2/20 0.40
ADRB3 P13945 2/20 0.40
EPHX2 P34913 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
HIF1A Q16665 1/20 0.40
SLC22A6 Q4U2R8 1/20 0.40
SLC22A8 Q8TCC7 1/20 0.40
LMNA P02545 2/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
PKM P14618 1/20 0.39
APEX1 P27695 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PRSS1 P07477 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27467816 0.82 NPC1 (0.47) NPC1RAB9ACA2ADRB2ADRB1
SCHEMBL25159032 0.81 NPC1 (0.53) NPC1RAB9ACA2KDM4EMAPT
SCHEMBL9087368 0.77 EPHX2 (0.43) NPC1RAB9ACA2ADRB2ADRB1
SCHEMBL9087370 0.77 EPHX2 (0.43) NPC1RAB9ACA2ADRB2ADRB1
SCHEMBL9237734 0.77 RAB9A (0.61) NPC1RAB9ACA2MAPTPOLB
SCHEMBL9237730 0.77 RAB9A (0.61) NPC1RAB9ACA2MAPTPOLB
SCHEMBL2486907 0.77 PRSS1 (0.49) KDM4ELMNAMEN1POLBKMT2A
SCHEMBL9087240 0.75 P2RY12 (0.42) NPC1RAB9ACA2ADRB2ADRB1
SCHEMBL9556410 0.75 P2RY12 (0.42) NPC1RAB9ACA2ADRB2ADRB1
SCHEMBL9087244 0.75 P2RY12 (0.42) NPC1RAB9ACA2ADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012419-B2 Methods and compositions related to eosinophil regulation UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2015-04-21 US disclosed
US-20100016410-A1 Methods and Compositions Related to Eosinophil Regulation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016410-A1 Methods and Compositions Related to Eosinophil Regulation EPX, CCL11, ELANE NPC1 2078/4885RAB9A 1532/4885CA2 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.